TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm” or the “Company”), a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) acquisition and management software solutions, confirms the USA Food and Drug Administration (“FDA”) has reduced the scope of their request for additional information for the Company’s premarket notification 510(k), Class … Read more
–> TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm” or the “Company”), a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, confirms the renewal of $600,000 in loans that would have matured December 31, 2018. The maturing loans were made to the Company in December 2016 as described … Read more
TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm” or the “Company” or “CCS”), a global medical provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, and Virginia-based connected health provider Creo Wellness, LLC (“CREO”) confirm the companies have committed to integrate CardioComm’s ECG monitoring service technologies and ECG devices … Read more
TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm” or the “Company”), a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, announced that it will makes its first issuance of shares under its online marketing and awareness program with AGORA Internet Relations Corp. (“AGORACOM”). The Company initially announced the … Read more
TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm” or the “Company”), a leading global provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, has completed its ISO 13485:2016 (“ISO“) certification in compliance with the Medical Device Single Audit Program (“MDSAP”), which is now mandatory under Health Canada requirements and … Read more
TORONTO, ONTARIO – Established medial electrocardiogram (“ECG”) software and device manufacturer CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today confirmed the appointment of a new Chief Financial Officer (“CFO”), Ms. Anne Burpee. Ms. Burpee is a bilingual Chartered Professional Accountant with more than 25 years of senior finance and executive experience in … Read more
TORONTO, ONTARIO – CardioComm Solutions, Inc. (“CardioComm” or the “Company”) (TSX VENTURE:EKG) a global medical provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, has completed its response to the USA Food and Drug Administration (“FDA”) for additional information following the Company’s filing of its premarket notification 510(k), Class II medical … Read more
TORONTO, ONTARIO – CardioComm Solutions, Inc. (“CardioComm” or the “Company”) (TSX VENTURE:EKG) a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, is pleased to announce that it is implementing an online marketing and awareness program through AGORA Internet Relations Corp. (“AGORACOM”). AGORACOM’s program will provide the Company a significant level … Read more
TORONTO, ONTARIO – CardioComm Solutions, Inc. (“CardioComm” or the “Company”) (TSX VENTURE:EKG) a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, today announced its joint partnership sales plans for the commercial launch of its newest software release designed to support an innovative and easy to use wireless, 12 lead ECG, … Read more
TORONTO, ONTARIO – CardioComm Solutions, Inc. (“CardioComm” or the “Company”) (TSX VENTURE:EKG) a leading global provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions confirmed today progress on a royalty licencing agreement with Redwood City, California-based Biotricty Inc. (“Biotricity”). The royalty payment phase became active following confirmation that all necessary clearance … Read more